BTG plc (BTG) Receives “Neutral” Rating from J P Morgan Chase & Co
Other equities research analysts also recently issued research reports about the company. Stifel Nicolaus reissued a buy rating and issued a GBX 800 ($10.52) price target on shares of BTG plc in a report on Wednesday, August 30th. Peel Hunt reissued a hold rating and issued a GBX 680 ($8.94) price target on shares of BTG plc in a report on Tuesday, October 31st. Numis Securities Ltd reissued a buy rating and issued a GBX 900 ($11.84) price target on shares of BTG plc in a report on Wednesday, October 18th. Finally, Deutsche Bank AG reissued a buy rating and issued a GBX 775 ($10.19) price target on shares of BTG plc in a report on Tuesday, November 7th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has an average rating of Buy and an average price target of GBX 779.13 ($10.25).
Shares of BTG plc (LON BTG) opened at GBX 715 ($9.40) on Wednesday. BTG plc has a 12-month low of GBX 528.36 ($6.95) and a 12-month high of GBX 779 ($10.25).
BTG plc (LON:BTG) last issued its quarterly earnings data on Tuesday, November 14th. The company reported GBX 21 ($0.28) earnings per share for the quarter, meeting analysts’ consensus estimates of GBX 21 ($0.28). BTG plc had a return on equity of 4.33% and a net margin of 7.26%. The company had revenue of £341.30 million for the quarter.
WARNING: “BTG plc (BTG) Receives “Neutral” Rating from J P Morgan Chase & Co” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/11/19/btg-plc-btg-receives-neutral-rating-from-j-p-morgan-chase-co.html.
BTG plc Company Profile
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Stock Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related stocks with our FREE daily email newsletter.